These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 37358745)

  • 1. LncRNA MAGI2-AS3-Encoded Polypeptide Restrains the Proliferation and Migration of Breast Cancer Cells.
    Zhang Z; Yi Y; Wang Z; Zhang H; Zhao Y; He R; Luo Y; Cui Z
    Mol Biotechnol; 2024 Jun; 66(6):1409-1423. PubMed ID: 37358745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. lncRNA MAGI2-AS3 suppresses castration-resistant prostate cancer proliferation and migration via the miR-106a-5p/RAB31 axis.
    Yang G; Li T; Liu J; Quan Z; Liu M; Guo Y; Wu Y; Ou L; Wu X; Zheng Y
    Genomics; 2023 Mar; 115(2):110599. PubMed ID: 36889366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LncRNA MAGI2-AS3 Inhibits Prostate Cancer Progression by Targeting the miR-142-3p.
    Hu R; Wu P; Liu J
    Horm Metab Res; 2022 Nov; 54(11):754-759. PubMed ID: 35944561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MAGI2-AS3 inhibits breast cancer by downregulating DNA methylation of MAGI2.
    Xu X; Yuan X; Ni J; Guo J; Gao Y; Yin W; Li F; Wei L; Zhang J
    J Cell Physiol; 2021 Feb; 236(2):1116-1130. PubMed ID: 32730644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LncRNA MAGI2-AS3 inhibites tumor progression by up-regulating STAM via interacting with miR-142-3p in clear cell renal cell carcinoma.
    Yang R; Chen Z; Ao S; Liang L; Chen Z; Duan X; Zeng G; Deng T
    Cell Signal; 2024 Jan; 113():110954. PubMed ID: 38084836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LncRNA MAGI2-AS3 is downregulated in non-small cell lung cancer and may be a sponge of miR-25.
    Sui Y; Chi W; Feng L; Jiang J
    BMC Pulm Med; 2020 Mar; 20(1):59. PubMed ID: 32138716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LncRNA MAGI2-As3 Suppresses the Proliferation and Invasion of Cervical Cancer by Sponging MiR-15b.
    Chai Y; Wang L; Qu Y; Hu Z
    J Healthc Eng; 2022; 2022():9707206. PubMed ID: 35126958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Roles of lncRNA MAGI2-AS3 in human cancers.
    Kai-Xin L; Cheng C; Rui L; Zheng-Wei S; Wen-Wen T; Peng X
    Biomed Pharmacother; 2021 Sep; 141():111812. PubMed ID: 34126355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long non-coding RNA MAGI2-AS3 inhibits breast cancer cell migration and invasion via sponging microRNA-374a.
    Du S; Hu W; Zhao Y; Zhou H; Wen W; Xu M; Zhao P; Liu K
    Cancer Biomark; 2019; 24(3):269-277. PubMed ID: 30883342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LncRNA MAGI2-AS3 inhibits bladder cancer progression by targeting the miR-31-5p/TNS1 axis.
    Tang C; Cai Y; Jiang H; Lv Z; Yang C; Xu H; Li Z; Li Y
    Aging (Albany NY); 2020 Nov; 12(24):25547-25563. PubMed ID: 33231563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel insights for lncRNA MAGI2-AS3 in solid tumors.
    Xue C; Li G; Lu J; Luo J; Jia J
    Biomed Pharmacother; 2021 May; 137():111429. PubMed ID: 33761624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long noncoding RNA MAGI2-AS3 inhibits bladder cancer progression through MAGI2/PTEN/epithelial-mesenchymal transition (EMT) axis.
    Shen D; Xu J; Cao X; Cao X; Tan H; Deng H
    Cancer Biomark; 2021; 30(2):155-165. PubMed ID: 33104021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of lncRNA MAGI2-AS3 in lipopolysaccharide-induced nucleus pulposus cells injury by regulating miR-374b-5p/interleukin-10 axis.
    Yu J; Li C
    Immun Inflamm Dis; 2023 Apr; 11(4):e772. PubMed ID: 37102649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long noncoding MAGI2-AS3 promotes colorectal cancer progression through regulating miR-3163/TMEM106B axis.
    Ren H; Li Z; Tang Z; Li J; Lang X
    J Cell Physiol; 2020 May; 235(5):4824-4833. PubMed ID: 31709544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long noncoding RNA MAGI2-AS3/miR-218-5p/GDPD5/SEC61A1 axis drives cellular proliferation and migration and confers cisplatin resistance in nasopharyngeal carcinoma.
    Cao C; Zhou S; Hu J
    Int Forum Allergy Rhinol; 2020 Aug; 10(8):1012-1023. PubMed ID: 32450008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LncRNA
    Li F; Hu Q; Pang Z; Xu X
    Cancer Biother Radiopharm; 2020 Feb; 35(1):72-76. PubMed ID: 31910343
    [No Abstract]   [Full Text] [Related]  

  • 17. Targeting MAGI2-AS3-modulated Akt-dependent ATP-binding cassette transporters as a possible strategy to reverse temozolomide resistance in temozolomide-resistant glioblastoma cells.
    Chen Z; Zhou J; Liu Y; Ni H; Zhou B
    Drug Dev Res; 2023 Nov; 84(7):1482-1495. PubMed ID: 37551766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MAGI2-AS3 suppresses MYC signaling to inhibit cell proliferation and migration in ovarian cancer through targeting miR-525-5p/MXD1 axis.
    Chang H; Zhang X; Li B; Meng X
    Cancer Med; 2020 Sep; 9(17):6377-6386. PubMed ID: 32681706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LncRNA MAGI2-AS3 inhibits tumor progression and angiogenesis by regulating ACY1 via interacting with transcription factor HEY1 in clear cell renal cell carcinoma.
    Wang G; Li H; Hou Y
    Cancer Gene Ther; 2022 May; 29(5):585-596. PubMed ID: 34002044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LncRNA MAGI2-AS3 inhibits hepatocellular carcinoma cell proliferation and migration by targeting the miR-374b-5p/SMG1 signaling pathway.
    Yin Z; Ma T; Yan J; Shi N; Zhang C; Lu X; Hou B; Jian Z
    J Cell Physiol; 2019 Aug; 234(10):18825-18836. PubMed ID: 30924168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.